Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab in Resectable dMMR Endometrial Cancer
NCT07369986Phase 2Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in endometrial cancer (EC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07369986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369986.